Stock Report

All about this stock under one free report Last Updated: 26-Oct-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Glaxosmithkline Pharma Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: GLAXO | BSE: 500660

₹2,404.70

up-down-arrow ₹-29.00 (-1.19%)

As on 23-Oct-2026IST

Market cap

info icon

₹40,739 Cr

Revenue (TTM)

info icon

₹3,955 Cr

P/E Ratio

info icon

38.1

P/B Ratio

info icon

16.2

Div. Yield

info icon

2.4 %

Edit peer-selector-edit
Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Market cap (₹ Cr)
 40,739 1,12,503 1,02,207 91,572 90,294
Revenue (₹ Cr)
 3,955 28,592 33,097 14,738 34,935
Net Profit (₹ Cr)
 1,068.15 4,492.20 2,759.70 2,055.11 3,712.74
Net Margin (%)
 26.05 14.92 8.03 13.64 10.42
RoE (%)
 52.98 18.78 7.30 13.60 10.38
Price to Earnings
 38.14 24.93 36.50 44.83 24.32
Price-To-Book
 16.16 4.17 2.63 5.44 2.32

Income Statement (₹ Cr)

Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Operating Revenue arrow
3,954.94 28,591.70 33,097.40 14,737.88 34,935.29
Total Income arrow
4,100.34 30,111.40 34,352.50 15,061.79 35,624.79
Total Expenditure arrow
2,601.44 21,334.70 28,236.90 10,911.05 27,850.01
EBITDA arrow
1,353.50 7,257.00 4,860.50 3,826.83 7,085.28
Depreciation arrow
66.76 1,724.60 2,141.40 893.20 1,859.31
EBIT arrow
1,286.74 5,532.40 2,719.10 2,933.63 5,225.97
Interest arrow
3.28 510.20 450.40 578.61 387.88
Other Income arrow
145.40 1,519.70 1,255.10 323.91 689.50
Exceptional Items arrow
20.62 -534.80 0.00 -129.75 -105.51
Profit before Tax arrow
1,449.48 6,007.10 3,523.80 2,549.18 5,422.08
Provision for Tax arrow
381.33 1,514.90 764.10 494.07 1,709.34
Profit after Tax arrow
1,068.15 4,492.20 2,759.70 2,055.11 3,712.74

Liabilities (₹ Cr)

Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Shareholder's Funds arrow
2,267.42 27,111.40 38,807.00 16,300.34 37,890.97
Minority Interest arrow
0.00 -79.70 40.20 -24.90 1.76
Non-Current Liabilities arrow
277.34 7,112.50 3,074.90 5,011.23 2,580.33
Current Liabilities arrow
1,779.11 15,711.90 15,430.30 6,507.25 18,039.01
Total Liabilities arrow
4,323.87 50,672.60 56,576.70 27,754.83 58,196.15

Assets (₹ Cr)

Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Non-Current Assets arrow
416.63 31,677.20 26,891.10 20,274.65 24,040.45
Current Assets arrow
3,606.18 19,906.10 29,732.20 6,954.20 32,708.75
Total Assets arrow
4,323.87 50,672.60 56,576.70 27,754.83 58,196.15
Total Debt* arrow
0.00 11,769.50 7,734.10 6,021.78 7,676.20
Net Current Assets arrow
1,827.07 4,194.20 14,301.90 446.95 14,669.74
Contingent Liabilities arrow
515.18 989.90 336.14 924.77 1,358.37

Cashflow (₹ Cr)

Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Cash From Operating Activities arrow
903.30 2,116.60 5,673.70 3,121.29 5,526.37
Cash Flow from Investing Activities arrow
396.98 -8,296.10 -6,549.30 -196.42 -3,458.61
Cash from Financing Activities arrow
-737.08 5,806.90 829.00 -2,952.69 -1,269.15
Net Cash Inflow / Outflow arrow
563.20 -372.60 -46.60 -27.82 798.61

Ratios

Profitability Ratios

 Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
ROCE (%) arrow
66.79 21.39 13.75 13.24 12.76
ROE (%) arrow
52.98 18.78 7.30 13.60 10.38
ROA (%) arrow
25.34 10.03 4.93 7.36 6.86
EBIT Margin (%) arrow
32.54 19.35 8.22 19.91 14.96
Net Margin (%) arrow
26.05 14.92 8.03 13.64 10.42
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Revenue Growth (%) arrow
5.75 21.11 -3.53 14.16 9.09
EBIT Growth (%) arrow
13.66 -8.99 -58.47 19.45 6.91
Net Profit Growth (%) arrow
12.41 -3.14 -51.77 8.09 8.63
EPS Growth (%) arrow
11.21 4.31 -51.50 12.27 11.88
Book Value Growth (%) arrow
16.12 13.19 12.99 13.74 16.04

Valuation Ratios

 Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Price / Earnings arrow
38.69 23.02 36.50 42.60 24.02
Price / Book Value arrow
16.16 4.17 2.63 5.44 2.32
Dividend Yield (%) arrow
2.37 0.09 0.65 0.05 0.25
EV/EBITDA arrow
28.04 16.13 21.17 24.97 12.33
Market Cap (₹ Cr) arrow
38,682.23 87,643.18 1,04,763.81 82,801.75 75,689.14

Solvency Ratios

 Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Debt to Equity arrow
0.00 0.12 0.00 0.17 0.02
Short term debt to equity ratio arrow
-- 0.16 0.16 0.04 0.16
Current Ratio arrow
2.03 1.27 1.93 1.07 1.81
Quick Ratio arrow
1.77 0.91 1.40 0.74 1.15
Interest Coverage arrow
442.91 12.77 8.82 5.41 14.98

Operating Efficiency Ratios

 Glaxosmithkline Pharma Zydus Lifesciences Dr. Reddy'S Labs Mankind Pharma Aurobindo Pharma
Debtors to sales (%) arrow
6.91 18.94 30.64 11.74 20.31
Asset Turnover arrow
0.94 0.64 0.59 0.53 0.65
Receivable days arrow
24.45 33.55 103.79 39.93 33.71
Inventory Days arrow
40.60 33.80 79.94 51.78 59.32
Payable days arrow
172.70 149.82 84.78 111.46 148.20
Cash Conversion Cycle arrow
-107.65 -82.46 98.95 -19.75 -55.17
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...